##### 



[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 EXHIBIT 10.62
 Execution Copy
 DRUG DISCOVERY COLLABORATION AGREEMENT
        
  Affiliate de jure de
facto
 Agreement Term
 1




---



##### 



Collaboration Technology
 Collaboration Patents
 Collaboration Know-How
 Consumer Price Index
 Control
 Field
 FTE
 JRC
 Hit Compound
 Hit Compound Criteria
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 2




---



##### 



Know-How
 Lead Compound
 Lead Compound Criteria
 NDA
 Net Sales
 Party
 Phase II
 Phase III
 Preparatory Know-How
 Preparatory Patents
 Product
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 3




---



##### 



Research Collaboration
 Research Plan
 Research Term
 Reserved Target
 Sublicensee provided
 Target(s)
 Third Party
 Valid Claim
 
 Goals
 Conduct of the Research Collaboration
 Target Selection
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 4




---



##### 



Research Plan
 Term and Termination of Research Collaboration
 Selection of Candidates for Further Development
 Records; Inspection
 Records
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 5




---



##### 



Reports and Information Exchange
 Post Research Collaboration Activities
 Exclusivity
 General
 Option
 Change of Control
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 6




---



##### 



Existing Library Compounds
 
 Joint Research Committee
 Membership
 Meetings
 Decision Making provided however provided
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 7




---



##### 



Research Licenses
 Grant from InterMune
 Grant from Array
 Commercial License
 License to Lead Compounds, Development Candidates and Corresponding Products
 Preparatory Know-How
 Sublicenses
 Marketing Rights
 License to Array
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 8




---



##### 



Third-Party Licenses
 No Implied Licenses
 No Products Other than Products
 
 Research Collaboration Funding
 Research Phase Payment Schedule
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 9




---



##### 



FTE Rate
 Non-FTE Costs
 PK Outsourcing
 Development Funding
 Milestones
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 10




---



##### 



Milestones
    
    Payment Amount1.[ * ]
    
    $
    150,0002.First human clinical trial of a Milestone Product initiated.
    
    $
    500,0003.[ * ]
    
    $
    [ * ]4.[ * ]
    
    $
    [ * ]5.[ * ]
    
    $
    [ * ]
    Royalties
 Products
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 11




---



##### 



Royalty Term
 Third Party Royalties provided
 Combination Products
 Compulsory License
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 12




---



##### 



Later Claims
 
 Royalty Reports and Payments
 Payment Method
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 13




---



##### 



Place of Royalty Payment; Currency Conversion
 Records; Inspection
 Taxes
 
 Due Diligence provided however
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 14




---



##### 



Reports
 
 Disclosure and Ownership of Inventions
    [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 15




---



##### 



Patent Prosecution
 Collaboration Technology
 Preparatory Patents mutatis mutandis provided
 Other Technology
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 16




---



##### 



Cooperation
 Certain Circumstances
 Enforcement and Defense
 Notice
 InterMune provided mutatis mutandis mutatis mutandis
 Cooperation; Costs and Recoveries
  [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 17




---



##### 



Confidential Information
     [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 18




---



##### 



Permitted Use and Disclosures provided
 Termination of Prior Agreement
 Nondisclosure of Terms provided
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 19




---



##### 



Publication
 
 InterMune
 Array
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 20




---



##### 



Disclaimer
 
 InterMune
 Array
 Indemnification Procedure provided
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 21




---



##### 



Term
 Termination for Breach provided however provided
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 22




---



##### 



Termination for Insolvency
 Permissive Termination
 Effect of Breach or Termination
 Accrued Rights and Obligations
 Return of Materials
 Survival Sections
 
 Governing Laws
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 23




---



##### 



forum non conveniens
 Waiver
 Assignment provided however
 Certain Companies mutatis mutandis
 Independent Contractors
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 24




---



##### 



Compliance with Laws
 Patent Marking
 Notices
 If to InterMune:
    
    InterMune, Inc.3280 Bayshore BoulevardBrisbane, California 94005Attention: General CounselFacsimile: (408) 508-0006If to Array:
    
    Array BioPharma Corporation3200 Walnut StreetBoulder, CO 80301Attention: Chief Operating OfficerFacsimile: (303) 381-6697With a copy to:
    
    Array BioPharma Corporation3200 Walnut StreetBoulder, CO 80301Attention: General CounselFacsimile: (303) 381-6639
 Severability
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 25




---



##### 



Advice of Counsel
 Performance Warranty
 Force Majeure provided however
 Complete Agreement
 Consultation
 Headings
 Counterparts
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 26




---



##### 



INTERMUNE, INC.
    
    
    
    ARRAY BIOPHARMA, INC.By:
    
    /s/ Lawrence M. Blatt
    
    
    
    By:
    
    /s/ David SnitmanName:
    
    Lawrence M. Blatt
    
    
    
    Name:
    
    David SnitmanTitle:
    
    VP Biopharmacology Research
    
    
    
    Title:
    
    COO
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 27




---



##### 



EXHIBIT A
 TARGETS
 Reserved Targets
 1.
    
    [ * ]2.
    
    [ * ]3.
    
    [ * ]4.
    
    [ * ]
 Target
 1.
    
    NS3/4 protease of the hepatitis C virus
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.
 28